| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | pla |
| Uniprot No | P0A921 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-289aa |
| 氨基酸序列 | QEATVKEVHDAPAVRGSIIANMLQEHDNPFTLYPYDTNYLIYTQTSDLNKEAIASYDWAENARKDEVKFQLSLAFPLWRGILGPNSVLGASYTQKSWWQLSNSEESSPFRETNYEPQLFLGFATDYRFAGWTLRDVEMGYNHDSNGRSDPTSRSWNRLYTRLMAENGNWLVEVKPWYVVGNTDDNPDITKYMGYYQLKIGYHLGDAVLSAKGQYNWNTGYGGAELGLSYPITKHVRLYTQVYSGYGESLIDYNFNQTRVGVGVMLNDLF |
| 预测分子量 | 32.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA重组蛋白的3篇虚构参考文献示例，涵盖不同研究方向：
---
1. **文献名称**: *"High-level expression and purification of recombinant human PLA2 in Escherichia coli for therapeutic applications"*
**作者**: Zhang, L., et al.
**摘要**: 本研究优化了大肠杆菌表达系统，成功实现重组人磷脂酶A2(PLA2)的高效表达与纯化。通过密码子优化和诱导条件调控，蛋白产量提升至120 mg/L，并验证其酶活性和稳定性，为抗炎药物开发奠定基础。
2. **文献名称**: *"PLA-based nanoparticles as carriers for sustained release of recombinant growth factors"*
**作者**: Lee, S., & Kim, H.
**摘要**: 探讨聚乳酸(PLA)纳米颗粒作为重组表皮生长因子(EGF)载体的可行性。实验表明，PLA纳米颗粒包封率超过85%，体外缓释达7天，显著促进细胞增殖，提示其在组织工程中的应用潜力。
3. **文献名称**: *"Functional characterization of a novel recombinant PLA variant with enhanced anti-bacterial activity"*
**作者**: Gupta, R., et al.
**摘要**: 设计并表达一种新型重组PLA突变体，其磷脂酶活性较野生型提高3倍。体外实验显示，该蛋白对革兰氏阳性菌的抑菌效果显著，为开发新型抗菌剂提供了依据。
---
**注**：以上文献为示例性内容，实际研究中请参考权威数据库(如PubMed、Web of Science)的实证文献。
**Background of Recombinant PLA Protein**
Recombinant PLA protein, commonly derived from *Streptococcus* species or engineered through synthetic biology, refers to a class of artificially produced proteins with applications in biomedicine, diagnostics, and biotechnology. PLA, or Protein A, is a cell wall-associated molecule originally known for its high affinity to the Fc region of immunoglobulins, particularly IgG antibodies. This binding property makes it invaluable in antibody purification processes, such as affinity chromatography, which is critical for manufacturing therapeutic monoclonal antibodies.
The development of recombinant PLA emerged to address limitations of native Protein A, including cost, scalability, and immunogenicity. Using genetic engineering, recombinant PLA variants are designed with optimized features, such as enhanced stability, reduced non-specific binding, or tailored binding specificity. These proteins are typically expressed in microbial systems like *E. coli* or yeast, enabling cost-effective large-scale production.
Beyond antibody purification, recombinant PLA has found roles in immunodetection assays, biosensors, and targeted drug delivery systems. Engineered PLA fusion proteins, for instance, can serve as versatile tools for visualizing cellular processes or delivering therapeutic payloads. Additionally, its use in research extends to studying protein-protein interactions and immune response mechanisms.
Despite its utility, challenges persist, such as minimizing residual host cell contaminants during production and adapting PLA variants to recognize diverse antibody subclasses. Ongoing innovations in protein engineering, including directed evolution and computational design, continue to refine recombinant PLA’s functionality, ensuring its relevance in advancing biotherapeutics and diagnostic technologies. Overall, recombinant PLA exemplifies the intersection of molecular biology and industrial application, driving progress in life sciences.
(Word count: 298)
×
